AstraZeneca PLC (LON:AZN - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £113.89 ($147.93) and traded as high as £120.20 ($156.12). AstraZeneca shares last traded at £119.94 ($155.79), with a volume of 1,437,588 shares.
Analyst Ratings Changes
A number of brokerages have issued reports on AZN. JPMorgan Chase & Co. reiterated an "overweight" rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Friday, March 7th. Finally, Berenberg Bank restated a "buy" rating and issued a GBX 140 ($1.82) price target on shares of AstraZeneca in a research note on Monday, January 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of "Moderate Buy" and a consensus target price of GBX 7,542.80 ($97.97).
View Our Latest Stock Analysis on AZN
AstraZeneca Trading Down 0.4 %
The business's 50 day moving average price is £114.59 and its two-hundred day moving average price is £113.58. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The company has a market capitalization of £228.11 billion, a price-to-earnings ratio of 32.50, a P/E/G ratio of 0.86 and a beta of 0.17.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
